Lower efficacy of bispecific antibodies in these settings has been previously reported in preclinical models of BCMA x CD3 bispecific antibodies [15] and is well described for the CD19 x CD3 bispecific antibody blinatumomab in acute lymphoblastic leukemia [16–18]. Here, CD19 is linked to acute lymphoblastic leukemia.